Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 21, 2015

Primary Completion Date

September 14, 2018

Study Completion Date

February 10, 2022

Conditions
Lymphoma Non-Hodgkin
Interventions
DRUG

Copanlisib (BAY80-6946)

Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).

Trial Locations (13)

460-0001

Nagoya

464-8681

Nagoya

466-8560

Nagoya

466-8650

Nagoya

467-8602

Nagoya

371-8511

Maebashi

650-0017

Kobe

980-8574

Sendai

104-0045

Chuo-ku

135-8550

Koto-ku

811-1395

Fukuoka

812-8582

Fukuoka

602-8566

Kyoto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY